TOD-IBD: Empowering Patients On-Demand
- Sponsor
- Franciscus Gasthuis
- Study ID
- NCT06179563
- Status
- Enrolling By Invitation
Conditions
- Inflammatory Bowel Diseases
- Patient Empowerment
- Self Efficacy
- Telemonitoring
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- On-Demand Telemonitoring — OTHERPatients assigned to the on-demand intervention group do not have to use the app at set time intervals but will be asked to use the app at their own discretion, in case of symptoms. This implies that patients have full control over their monitoring activities. Patients have the option to reach out to the hospital whenever they feel the need.
Study Details
Crohn's disease and Ulcerative Colitis, collectively known as Inflammatory Bowel Disease (IBD), impose a significant burden on patients and healthcare systems due to their chronic nature and complex treatment. This study aims to assess the effectiveness and safety of on-demand telemonitoring, as opposed to standard fixed-schedule telemonitoring, in managing IBD. The primary objective is to evaluate the impact of on-demand telemonitoring on the number of persistent flares over 12 months. The study involves a multicenter randomized controlled trial comparing standard telemonitoring, which includes regular completion of the Monitor IBD At Home questionnaire and fecal calprotectin home tests, with on-demand telemonitoring where patients use the app based on their symptoms. The study population includes adult patients with stable remission on maintenance therapy. Disease activity, measured by unplanned healthcare contacts, is the primary outcome, while secondary outcomes encompass clinical and patient-reported disease activity, quality of life, self-efficacy, patient activation, total healthcare contacts, safety, and costs. Baseline characteristics include patient, disease, and socio-demographic factors. This innovative approach has the potential to enhance patient autonomy, satisfaction, and self-management, while reducing the overall burden on the healthcare system.
Key Dates
- First listed
- Dec 22, 2023
- Start date
- Mar 26, 2025
- Status verified
- Aug 2025
- Primary completion
- Jul 1, 2027
- Completion
- Mar 1, 2028
Study Design
- Enrollment
- 422 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- No Intervention: Standard telemonitoringPatients will be monitored according to a fixed telemonitoring schedule at their treating hospitals, based on the patient's medication type and in adherence to national and international guidelines.
- Experimental: On-Demand TelemonitoringPatients will have the flexibility to use the telemonitoring application at their own discretion
Primary Outcome Measure
Persistent Flares [ Time Frame: 12 months ]
Related Studies
- The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic TestingRecruiting · University of Chicago · Chicago, Illinois
- Improving the Quality of Care for Adults With Inflammatory Bowel DiseaseEnrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
- CorEvitas Inflammatory Bowel Disease (IBD) RegistryEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial)Enrolling By Invitation · Boston Children's Hospital · Boston, Massachusetts